• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
QRX
Click for more information
0.00% 2.8¢

QRXPHARMA LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
QRX Appendix 4C - Quarter Ended 31 March 2018PRICE SENSITIVE20/04/18
QRX Half Yearly Report and Accounts - 31 December 2017PRICE SENSITIVE26/02/18
QRX Suspension from Official QuotationPRICE SENSITIVE22/05/15
QRX Appendix 4C - Quarter Ended 31 March 2015PRICE SENSITIVE22/04/15
QRX Response to ASX Price QueryPRICE SENSITIVE02/04/15
QRX Half Yearly Report and Accounts - 31 December 2014PRICE SENSITIVE25/02/15
QRX Appendix 4C - Quarter Ended 31 December 2014PRICE SENSITIVE27/01/15
QRX Appendix 4C - Quarter Ended 30 September 2014PRICE SENSITIVE24/10/14
QRX Preliminary Final Report - 30 June 2014PRICE SENSITIVE27/08/14
QRX QRxPharma Halts Moxduo DevelopmentPRICE SENSITIVE14/08/14
QRX Appendix 4C - Quarter Ended 30 June 2014PRICE SENSITIVE17/07/14
QRXComplete Response Letter from FDA regarding Moxduo NDAPRICE SENSITIVE26/05/14
QRXDr. Edward Rudnic Appointed CEO of QRxPharmaPRICE SENSITIVE02/05/14
QRXAppendix 4C - Quarter Ended 31 March 2014PRICE SENSITIVE29/04/14
QRXQRxPharma Issues Statement On Moxduo Advisory CommitteePRICE SENSITIVE23/04/14
QRXTrading HaltPRICE SENSITIVE17/04/14
QRXHalf Yearly Report and Accounts - 31 December 2013PRICE SENSITIVE25/02/14
QRXAppendix 4C - Quarter Ended 31 December 2013PRICE SENSITIVE29/01/14
QRX$4.1 Million SPP Completes A$11.6 Million Capital RaisingPRICE SENSITIVE13/12/13
QRXMOXDUO License with TEVA for Commercialisation in IsraelPRICE SENSITIVE27/11/13
QRXQRxPharma Refiles MOXDUO New Drug Application with the FDAPRICE SENSITIVE26/11/13
QRXSuccessful Completion of A$7.5 Million PlacementPRICE SENSITIVE13/11/13
QRXTrading HaltPRICE SENSITIVE11/11/13
QRXAppendix 4C - Quarter Ended 30 September 2013PRICE SENSITIVE28/10/13
QRXQRxPharma Extends MOXDUO License with AspenPRICE SENSITIVE15/10/13
QRXQRxPharma reports Positive Meeting with the FDA on MOXDUOPRICE SENSITIVE09/10/13
QRXQRxPharma Announces MOXDUO License with AspenPRICE SENSITIVE11/09/13
QRXPreliminary Final Report - 30 June 2013PRICE SENSITIVE29/08/13
QRXComplete Response Letter from FDA regarding MOXDUO NDAPRICE SENSITIVE28/08/13
QRXTrading HaltPRICE SENSITIVE26/08/13
QRXAppendix 4C - Quarter Ended 30 June 2013PRICE SENSITIVE26/07/13
QRXQRxPharma Announces Collaboration with AesicaPRICE SENSITIVE22/07/13
QRXQRxPharma Updates MOXDUO NDA ReviewPRICE SENSITIVE26/06/13
QRXTrading HaltPRICE SENSITIVE26/06/13
QRXQRxPharma Granted US Patent on Hybrid OpioidsPRICE SENSITIVE12/06/13
QRXFDA sets 17 July 2013 for MOXDUO Advisory Committee MeetingPRICE SENSITIVE17/05/13
QRXAppendix 4C - Quarter Ended 31 March 2013PRICE SENSITIVE29/04/13
QRXQRxPharma Resubmits MOXDUO New Drug Application to the FDAPRICE SENSITIVE28/02/13
QRXHalf Yearly Report and Accounts - 31 December 2012PRICE SENSITIVE18/02/13
QRXAppendix 4C - Quarter Ended 31 December 2012PRICE SENSITIVE24/01/13
QRXPath Forward For Resubmission of MOXDUO NDAPRICE SENSITIVE16/01/13
QRXAppendix 4C - Quarter Ended 30 September 2012PRICE SENSITIVE26/10/12
QRXStrategic Collaboration with Paladin LabsPRICE SENSITIVE10/10/12
QRXPreliminary Final Report - 30 June 2012PRICE SENSITIVE30/08/12
QRXProductive Meeting With FDA Regarding MOXDUO NDAPRICE SENSITIVE20/08/12
QRXAppendix 4C - Quarter Ended 30 June 2012PRICE SENSITIVE24/07/12
QRXComplete Response Letter from FDA regarding MOXDUO NDAPRICE SENSITIVE27/06/12
QRXTrading HaltPRICE SENSITIVE25/06/12
QRXQRxPharma Granted Additional US Patent on MoxDuoPRICE SENSITIVE23/05/12
QRXAppendix 4C - Quarter Ended 31 March 2012PRICE SENSITIVE16/04/12
QRXSuccessful Completion of Phase 1 Studies for MoxDuo CRPRICE SENSITIVE11/04/12
QRXQRxPharma Signs License and Option Agreement with ActavisPRICE SENSITIVE19/03/12
QRXHalf Yearly Report and Accounts - 31 December 2011PRICE SENSITIVE24/02/12
QRXAppendix 4C - Quarter Ended 31 December 2011PRICE SENSITIVE30/01/12
QRXQRxPharma Announces Strategic Partnership with ActavisPRICE SENSITIVE21/12/11
QRXTrading HaltPRICE SENSITIVE20/12/11
QRXPDUFA Target Date for FDA Action on MoxDuo IR NDA GrantedPRICE SENSITIVE08/11/11
QRXAppendix 4C - Quarter Ended 30 September 2011PRICE SENSITIVE27/10/11
QRXQRxPharma Completes NDA Submission for MoxDuo IRPRICE SENSITIVE25/08/11
QRXPreliminary Final Report - 30 June 2011PRICE SENSITIVE18/08/11
QRXAppendix 4C - Quarter Ended 30 June 2011PRICE SENSITIVE28/07/11
QRXQRxPharma Announces A$35 Million Capital RaisingPRICE SENSITIVE22/07/11
QRXTrading HaltPRICE SENSITIVE20/07/11
QRXQRxPharma Announces NDA Filing for MoxDuo IRPRICE SENSITIVE18/07/11
QRXAdditional Data on MoxDuo IR Comparative Safety StudyPRICE SENSITIVE29/06/11
QRXSuccessful Completion MoxDuo IR Comparative Safety StudyPRICE SENSITIVE14/06/11
QRXAppendix 4C - Quarterly Report 31 March 2011PRICE SENSITIVE28/04/11
QRXEnrolment of MoxDuo IR Comparative Safety Study CompletedPRICE SENSITIVE27/04/11
QRXUSPTO Issues QRxPharma a New Patent for MoxDuo IRPRICE SENSITIVE14/04/11
QRXQRxPharma on Track to File New Drug Application Mid-YearPRICE SENSITIVE28/03/11
QRXHalf Yearly Report and Accounts -31 December 2010PRICE SENSITIVE21/02/11
QRXSuccessful Completion Third Pivotal MoxDuo IR Phase 3PRICE SENSITIVE21/02/11
QRXAppendix 4C - 31 December 2010PRICE SENSITIVE27/01/11
QRXInitiation of Phase 3 Comparative Safety Study of MoxDuo IRPRICE SENSITIVE24/01/11
QRXEnrolment of Pivotal MoxDuo IR Phase 3 Study CompletedPRICE SENSITIVE06/12/10
QRXAdditional U.S.Therapeutic Discovery Project Grant AwardedPRICE SENSITIVE08/11/10
QRXMoxDuo Awarded U.S. Therapeutic Discovery Project GrantsPRICE SENSITIVE04/11/10
QRXAppendix 4C -30 September 2010PRICE SENSITIVE27/10/10
QRXA$14 Million Placement together with a Share Purchase PlanPRICE SENSITIVE01/10/10
QRXTrading HaltPRICE SENSITIVE29/09/10
QRXInterim Analysis of Final Pivotal Phase 3 Study MoxDuoIRPRICE SENSITIVE01/09/10
QRXPreliminary Final Report - 30 June 2010PRICE SENSITIVE26/08/10
QRXPositive Phase 2 Proof of Concept Data for MoxDuoIVPRICE SENSITIVE09/08/10
QRXPositive Scientific Advice Meetings in Europe MoxDou IRPRICE SENSITIVE26/07/10
QRXAppendix 4C - 30 June 2010PRICE SENSITIVE26/07/10
QRXPhase 1 PK Study for MoxDuoCR Tablet Formula SuccessfulPRICE SENSITIVE10/05/10
QRXResponse to ASX Query - Appendix 4CPRICE SENSITIVE06/05/10
QRXPhase 3 Combination Rule Study for MoxDuo IR Additional DataPRICE SENSITIVE04/05/10
QRXAppendix 4C - Quarterly Report 31 March 2010PRICE SENSITIVE27/04/10
QRXPhase 3 Combination Rule Study for MoxDuoIR SuccessfulPRICE SENSITIVE14/04/10
QRXPhase 1 Trial of Controlled-Release Dual-Opioid InitiatedPRICE SENSITIVE30/03/10
QRXStrategic Alliance for Development of MoxDuo IVPRICE SENSITIVE23/02/10
QRXHalf Yearly Report and Accounts - 31 December 2009PRICE SENSITIVE17/02/10
QRXQRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIRPRICE SENSITIVE10/02/10
QRXAppendix 4C - Quarterly Report 31 December 2009PRICE SENSITIVE27/01/10
QRXQRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIRPRICE SENSITIVE30/11/09
QRXReinstatement to Official QuotationPRICE SENSITIVE16/11/09
QRXA$21.6 Million Fully Underwritten Placement and Rights IssuePRICE SENSITIVE16/11/09
QRXSuspension from Official QuotationPRICE SENSITIVE13/11/09
QRXQRxPharma Investor Update and Capital RaisingPRICE SENSITIVE11/11/09
QRX Appendix 4C - Quarter Ended 31 March 2018
20/04/18PRICE SENSITIVE
QRX Half Yearly Report and Accounts - 31 December 2017
26/02/18PRICE SENSITIVE
QRX Suspension from Official Quotation
22/05/15PRICE SENSITIVE
QRX Appendix 4C - Quarter Ended 31 March 2015
22/04/15PRICE SENSITIVE
QRX Response to ASX Price Query
02/04/15PRICE SENSITIVE
QRX Half Yearly Report and Accounts - 31 December 2014
25/02/15PRICE SENSITIVE
QRX Appendix 4C - Quarter Ended 31 December 2014
27/01/15PRICE SENSITIVE
QRX Appendix 4C - Quarter Ended 30 September 2014
24/10/14PRICE SENSITIVE
QRX Preliminary Final Report - 30 June 2014
27/08/14PRICE SENSITIVE
QRX QRxPharma Halts Moxduo Development
14/08/14PRICE SENSITIVE
QRX Appendix 4C - Quarter Ended 30 June 2014
17/07/14PRICE SENSITIVE
QRXComplete Response Letter from FDA regarding Moxduo NDA
26/05/14PRICE SENSITIVE
QRXDr. Edward Rudnic Appointed CEO of QRxPharma
02/05/14PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 March 2014
29/04/14PRICE SENSITIVE
QRXQRxPharma Issues Statement On Moxduo Advisory Committee
23/04/14PRICE SENSITIVE
QRXTrading Halt
17/04/14PRICE SENSITIVE
QRXHalf Yearly Report and Accounts - 31 December 2013
25/02/14PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 December 2013
29/01/14PRICE SENSITIVE
QRX$4.1 Million SPP Completes A$11.6 Million Capital Raising
13/12/13PRICE SENSITIVE
QRXMOXDUO License with TEVA for Commercialisation in Israel
27/11/13PRICE SENSITIVE
QRXQRxPharma Refiles MOXDUO New Drug Application with the FDA
26/11/13PRICE SENSITIVE
QRXSuccessful Completion of A$7.5 Million Placement
13/11/13PRICE SENSITIVE
QRXTrading Halt
11/11/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 September 2013
28/10/13PRICE SENSITIVE
QRXQRxPharma Extends MOXDUO License with Aspen
15/10/13PRICE SENSITIVE
QRXQRxPharma reports Positive Meeting with the FDA on MOXDUO
09/10/13PRICE SENSITIVE
QRXQRxPharma Announces MOXDUO License with Aspen
11/09/13PRICE SENSITIVE
QRXPreliminary Final Report - 30 June 2013
29/08/13PRICE SENSITIVE
QRXComplete Response Letter from FDA regarding MOXDUO NDA
28/08/13PRICE SENSITIVE
QRXTrading Halt
26/08/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 June 2013
26/07/13PRICE SENSITIVE
QRXQRxPharma Announces Collaboration with Aesica
22/07/13PRICE SENSITIVE
QRXQRxPharma Updates MOXDUO NDA Review
26/06/13PRICE SENSITIVE
QRXTrading Halt
26/06/13PRICE SENSITIVE
QRXQRxPharma Granted US Patent on Hybrid Opioids
12/06/13PRICE SENSITIVE
QRXFDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting
17/05/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 March 2013
29/04/13PRICE SENSITIVE
QRXQRxPharma Resubmits MOXDUO New Drug Application to the FDA
28/02/13PRICE SENSITIVE
QRXHalf Yearly Report and Accounts - 31 December 2012
18/02/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 December 2012
24/01/13PRICE SENSITIVE
QRXPath Forward For Resubmission of MOXDUO NDA
16/01/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 September 2012
26/10/12PRICE SENSITIVE
QRXStrategic Collaboration with Paladin Labs
10/10/12PRICE SENSITIVE
QRXPreliminary Final Report - 30 June 2012
30/08/12PRICE SENSITIVE
QRXProductive Meeting With FDA Regarding MOXDUO NDA
20/08/12PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 June 2012
24/07/12PRICE SENSITIVE
QRXComplete Response Letter from FDA regarding MOXDUO NDA
27/06/12PRICE SENSITIVE
QRXTrading Halt
25/06/12PRICE SENSITIVE
QRXQRxPharma Granted Additional US Patent on MoxDuo
23/05/12PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 March 2012
16/04/12PRICE SENSITIVE
QRXSuccessful Completion of Phase 1 Studies for MoxDuo CR
11/04/12PRICE SENSITIVE
QRXQRxPharma Signs License and Option Agreement with Actavis
19/03/12PRICE SENSITIVE
QRXHalf Yearly Report and Accounts - 31 December 2011
24/02/12PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 December 2011
30/01/12PRICE SENSITIVE
QRXQRxPharma Announces Strategic Partnership with Actavis
21/12/11PRICE SENSITIVE
QRXTrading Halt
20/12/11PRICE SENSITIVE
QRXPDUFA Target Date for FDA Action on MoxDuo IR NDA Granted
08/11/11PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 September 2011
27/10/11PRICE SENSITIVE
QRXQRxPharma Completes NDA Submission for MoxDuo IR
25/08/11PRICE SENSITIVE
QRXPreliminary Final Report - 30 June 2011
18/08/11PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 June 2011
28/07/11PRICE SENSITIVE
QRXQRxPharma Announces A$35 Million Capital Raising
22/07/11PRICE SENSITIVE
QRXTrading Halt
20/07/11PRICE SENSITIVE
QRXQRxPharma Announces NDA Filing for MoxDuo IR
18/07/11PRICE SENSITIVE
QRXAdditional Data on MoxDuo IR Comparative Safety Study
29/06/11PRICE SENSITIVE
QRXSuccessful Completion MoxDuo IR Comparative Safety Study
14/06/11PRICE SENSITIVE
QRXAppendix 4C - Quarterly Report 31 March 2011
28/04/11PRICE SENSITIVE
QRXEnrolment of MoxDuo IR Comparative Safety Study Completed
27/04/11PRICE SENSITIVE
QRXUSPTO Issues QRxPharma a New Patent for MoxDuo IR
14/04/11PRICE SENSITIVE
QRXQRxPharma on Track to File New Drug Application Mid-Year
28/03/11PRICE SENSITIVE
QRXHalf Yearly Report and Accounts -31 December 2010
21/02/11PRICE SENSITIVE
QRXSuccessful Completion Third Pivotal MoxDuo IR Phase 3
21/02/11PRICE SENSITIVE
QRXAppendix 4C - 31 December 2010
27/01/11PRICE SENSITIVE
QRXInitiation of Phase 3 Comparative Safety Study of MoxDuo IR
24/01/11PRICE SENSITIVE
QRXEnrolment of Pivotal MoxDuo IR Phase 3 Study Completed
06/12/10PRICE SENSITIVE
QRXAdditional U.S.Therapeutic Discovery Project Grant Awarded
08/11/10PRICE SENSITIVE
QRXMoxDuo Awarded U.S. Therapeutic Discovery Project Grants
04/11/10PRICE SENSITIVE
QRXAppendix 4C -30 September 2010
27/10/10PRICE SENSITIVE
QRXA$14 Million Placement together with a Share Purchase Plan
01/10/10PRICE SENSITIVE
QRXTrading Halt
29/09/10PRICE SENSITIVE
QRXInterim Analysis of Final Pivotal Phase 3 Study MoxDuoIR
01/09/10PRICE SENSITIVE
QRXPreliminary Final Report - 30 June 2010
26/08/10PRICE SENSITIVE
QRXPositive Phase 2 Proof of Concept Data for MoxDuoIV
09/08/10PRICE SENSITIVE
QRXPositive Scientific Advice Meetings in Europe MoxDou IR
26/07/10PRICE SENSITIVE
QRXAppendix 4C - 30 June 2010
26/07/10PRICE SENSITIVE
QRXPhase 1 PK Study for MoxDuoCR Tablet Formula Successful
10/05/10PRICE SENSITIVE
QRXResponse to ASX Query - Appendix 4C
06/05/10PRICE SENSITIVE
QRXPhase 3 Combination Rule Study for MoxDuo IR Additional Data
04/05/10PRICE SENSITIVE
QRXAppendix 4C - Quarterly Report 31 March 2010
27/04/10PRICE SENSITIVE
QRXPhase 3 Combination Rule Study for MoxDuoIR Successful
14/04/10PRICE SENSITIVE
QRXPhase 1 Trial of Controlled-Release Dual-Opioid Initiated
30/03/10PRICE SENSITIVE
QRXStrategic Alliance for Development of MoxDuo IV
23/02/10PRICE SENSITIVE
QRXHalf Yearly Report and Accounts - 31 December 2009
17/02/10PRICE SENSITIVE
QRXQRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIR
10/02/10PRICE SENSITIVE
QRXAppendix 4C - Quarterly Report 31 December 2009
27/01/10PRICE SENSITIVE
QRXQRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIR
30/11/09PRICE SENSITIVE
QRXReinstatement to Official Quotation
16/11/09PRICE SENSITIVE
QRXA$21.6 Million Fully Underwritten Placement and Rights Issue
16/11/09PRICE SENSITIVE
QRXSuspension from Official Quotation
13/11/09PRICE SENSITIVE
QRXQRxPharma Investor Update and Capital Raising
11/11/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due to organised crime links.
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.